The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
The bioavailability of oral and intravenous cimetidine and ranitidine was studied in patients with compensated liver cirrhosis. Single doses of 200 and 400 mg cimetidine were used for both administration routes, while ranitidine was administered in doses of 150 mg orally or 50 mg i.v. Plasma concentrations and urinary recovery were determined by the HPLC method. The pharmacokinetics of both of these drugs in the cirrhotic patients did not differ from those found in normal subjects. The two doses of cimetidine given i.v. gave rise to the same plasma concentrations, while after oral administration, 400 mg produced higher plasma concentrations than 200 mg. As to the pharmacokinetic parameters, neither cimetidine nor ranitidine administered i.v. offered any further advantages compared to the oral route. The urinary recovery of both cimetidine and ranitidine was higher after intravenous than after oral administration. It is concluded therefore that the pharmacokinetics of cimetidine and ranitidine is not altered in compensated liver cirrhosis.
D000284:Administration, Oral; D002927:Cimetidine / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008103:Liver Cirrhosis / Q000097:blood*; D008297:Male; D008657:Metabolic Clearance Rate; D011899:Ranitidine / Q000097:blood*
D002927:Cimetidine; D011899:Ranitidine